You are here

Neurostimulator Device Approved to Treat Epilepsy

Monthly seizure rates reduced (November 14)

The FDA has approved a device to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications.

The RNS Stimulator (Neuropace, Inc.) consists of a small neurostimulator implanted within the skull under the scalp. The neurostimulator is connected to one or two electrodes that are placed where the seizures are suspected to originate within the brain or on the surface of the brain.

Epilepsy produces seizures affecting various mental and physical functions. Seizures happen when clusters of nerve cells in the brain signal abnormally, which may briefly alter a person’s consciousness, movements, or actions.

The FDA’s approval is supported by a 3-month randomized controlled study of 191 patients with drug-resistant epilepsy.

The study showed that by 3 months after the implanted device was turned on (active use), patients experienced a nearly 38% reduction in the average number of seizures per month, compared with an approximately 17% reduction in the average number of seizures per month in patients in whom the implanted device was turned off. At the end of 3 months, the median reduction in seizures, which reflects a more-typical patient experience, was 34% with active use and about 19% with the device turned off. During the trial, 29% of patients with an active device experienced at least a 50% reduction in the overall number of seizures, compared with 27% of those with the implanted device turned off.

The most frequent adverse events were implant-site infection and premature battery depletion.

Source: FDA; November 14, 2013.

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers